ArticleInternational journal of clinical and experimental pathology2018
miR-424 promotes cardiac ischemia/reperfusion injury by direct targeting of CRISPLD2 and regulating cardiomyocyte pyroptosis.
Article in International journal of clinical and experimental pathology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 24 citations in OpenAlex.
- CRISPLD2 Attenuates Intervertebral Disc Degeneration by Suppressing Oxidative Stress-Induced Ferroptosis through the miR-548I-IL17A Axis.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Fraxinellone mitigates acute lung injury by targeting HIF-1α to suppress pyroptosis and inflammation.Frontiers in immunology · 2026Article
- LDHA exacerbates myocardial ischemia-reperfusion injury through inducing NLRP3 lactylation.BMC cardiovascular disorders · 2024Article
- Mechanism of METTL3-Mediated mCardiovascular drugs and therapy · 2023Article
- LncRNA Rian reduces cardiomyocyte pyroptosis and alleviates myocardial ischemia-reperfusion injury by regulating by the miR-17-5p/CCND1 axis.Hypertension research : official journal of the Japanese Society of Hypertension · 2022Article
- Bioinformatics analysis to identify potential biomarkers and therapeutic targets for ST-segment-elevation myocardial infarction-related ischemic stroke.Frontiers in neurology · 2022Article
- Non-coding RNAs in necroptosis, pyroptosis, and ferroptosis in cardiovascular diseases.Frontiers in cardiovascular medicine · 2022Review
- Pyroptosis in inflammatory diseases and cancer.Theranostics · 2022Review
- Article
- Regulation of pyroptosis in cardiovascular pathologies: Role of noncoding RNAs.Molecular therapy. Nucleic acids · 2021Review
- Identification of candidate biomarkers and therapeutic agents for heart failure by bioinformatics analysis.BMC cardiovascular disorders · 2021Article
- IP3R1 regulates CaCell death discovery · 2021Article
- microRNAs involved in psoriasis and cardiovascular diseases.Vascular biology (Bristol, England) · 2021Review
- A narrative review of the roles of the miR-15/107 family in heart disease: lessons and prospects for heart disease.Annals of translational medicine · 2021Review
- MiR-424 is over-expressed and attenuates ischemia-reperfusion kidney injury via p53 and death receptor 6 pathway.American journal of translational research · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
As a complex pathophysiological event, myocardial ischemia/reperfusion injury (IRI) can cause heart failure, which has been associated with pyroptosis, a pro-inflammatory programmed cell death. Small endogenous non-coding RNAs have been shown to be involved in myocardial IRI. In the present study, we aimed to investigate whether miR-424 modulated pyroptosis in response to myocardial IRI and determine its underlying regulatory mechanism. An
Indexed as
Identifiers
31949697PMC6962881W3011604768What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.